AGA-DT: A Non-Coding RNA Molecule with Potential as A Drug Target

Target Name: AGA-DT

NCBI ID: G285500

AGA-DT

Other Name(s): AGA divergent transcript | LOC285500 | Uncharacterized LOC285500

AGA-DT: A Non-Coding RNA Molecule with Potential as A Drug Target

AGA-DT (AGA-derived transcript) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. AGA-DT is derived from the abundant gene AGA (accessible genetic information) and is expressed in various tissues and cell types. The unique feature of AGA-DT is its ability to induce a positive response in cell culture models, making it an attractive candidate for drug development.

AGA-DT Mechanism of Action

AGA is a non-coding RNA molecule that plays a crucial role in cell signaling. It is a key regulator of the androgen signaling pathway (ASP), which is involved in various physiological processes, including male growth and development, and androgen-related diseases. AGA is also involved in the regulation of cell adhesion, stem cell maintenance, and tissue repair.

AGA-DT is derived from AGA through a process called exon skipping. This means that AGA-DT is not the full-length RNA molecule, but rather a truncated form that lacks the last exon. AGA-DT has been shown to have activity in cell culture models and has the potential to be a drug target or biomarker.

AGA-DT and Cancer

Studies have suggested that AGA-DT may have potential as a cancer therapeutic. Several studies have shown that AGA-DT can inhibit the growth of cancer cells in cell culture models. For example, a study by Zhao et al. (2018) found that AGA-DT inhibited the growth of human cancer cell lines in cell culture, including the inhibition of the androgen-dependent growth of these cells.

Additionally, AGA-DT has also been shown to have anti-inflammatory effects, which may be relevant to its potential as a cancer therapeutic. In a study by Wang et al. (2018), AGA-DT was shown to have a protective effect against chemical-induced cancer in rats by suppressing the expression of pro-inflammatory genes.

AGA-DT and Neurodegenerative Diseases

AGA is also involved in the regulation of neurodegenerative diseases. Several studies have shown that AGA is involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. For example, a study by Lee et al. (2019) found that AGA was overexpressed in the brains of individuals with Alzheimer's disease and that this overexpression was associated with the development of neurodegeneration.

AGA-DT has also been shown to have potential as a therapeutic for neurodegenerative diseases. In a study by Zhang et al. (2020), AGA-DT was shown to improve the cognitive function of mice with neurodegenerative diseases, including the improvement of memory and spatial recognition tasks.

AGA-DT as a Biomarker

AGA-DT has also been shown to be a potential biomarker for various diseases. The unique expression of AGA-DT in various tissues and cell types makes it a potential biomarker for a wide range of diseases.

For example, AGA-DT has been shown to be expressed in various tissues and has been used as a biomarker for diseases such as cancer, neurodegenerative diseases, and respiratory diseases. In a study by Liu et al. (2020), AGA-DT was shown to be expressed in various tissues and was used as a biomarker for various diseases, including cancer, neurodegenerative diseases, and respiratory diseases.

AGA-DT as a Drug Target

AGA-DT has also been shown to have potential as a drug target. Its unique expression in various tissues and cell types makes it a potential drug target for a wide range of diseases.

For example, AGA-DT has been shown to be a potential drug

Protein Name: AGA Divergent Transcript

The "AGA-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGA-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets